AZN Latest Press Releases

-- February 11, 2026 --

AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US Business Wire 9:00 AM

-- February 10, 2026 --

AstraZeneca results: FY and Q4 2025 Business Wire 7:00 AM

-- February 3, 2026 --

DATROWAY (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy Business Wire 7:00 AM

DATROWAY Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy Business Wire 2:30 AM

-- February 2, 2026 --

AstraZeneca begins trading on the New York Stock Exchange Business Wire 7:00 AM

-- January 19, 2026 --

ENHERTU Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer Business Wire 2:30 AM

-- January 13, 2026 --

TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer Business Wire 7:00 AM

-- January 9, 2026 --

Walmart Inc. to Join the Nasdaq-100 Index Beginning January 20th, 2026 Globe Newswire 8:00 PM

-- January 8, 2026 --

Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit Business Wire 7:00 AM

-- December 22, 2025 --

ENHERTU (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer Business Wire 7:00 AM

When Wall Street Rotates, Biotech Innovators Emerge: The Untapped Opportunities in Oncology Yolowire 6:53 AM

ENHERTU Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer Business Wire 2:30 AM

DESTINY-Endometrial02 Phase 3 Trial of ENHERTU Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer Business Wire 2:30 AM

-- December 18, 2025 --

DATROWAY Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy Business Wire 2:30 AM

-- December 15, 2025 --

ENHERTU (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer Business Wire 4:29 PM

ENHERTU Plus Pertuzumab Approved in the U.S. as First New Treatment in More Than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer Business Wire 2:30 PM

-- December 9, 2025 --

DESTINY-Ovarian01 Phase 3 Trial of ENHERTU Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced Ovarian Cancer Business Wire 7:00 AM

-- December 4, 2025 --

Salesforce's Agentforce Life Sciences Selected by AstraZeneca as Its Unified Global Platform to Help Transform Customer Engagement Business Wire 4:00 PM

AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH Business Wire 7:00 AM

-- December 2, 2025 --

Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension Business Wire 9:18 AM

-- December 1, 2025 --

Vistagen Appoints Nick Tressler as Chief Financial Officer Business Wire 8:30 AM

-- November 26, 2025 --

IMFINZI approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers Business Wire 7:00 AM

-- November 21, 2025 --

AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth Business Wire 2:05 PM

-- November 9, 2025 --

Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial Business Wire 4:33 PM

-- November 7, 2025 --

Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of disease Business Wire 9:00 AM

-- November 6, 2025 --

Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy Globe Newswire 7:00 AM

AstraZeneca's 9M and Q3 2025 Financial Results Business Wire 7:00 AM

-- October 30, 2025 --

DESTINY-Lung06 Phase 3 Trial of ENHERTU Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Squamous Non-Small Cell Lung Cancer Business Wire 9:00 PM

-- October 19, 2025 --

DATROWAY (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option Business Wire 7:00 AM

DATROWAY Demonstrated an Unprecedented Median Overall Survival Improvement of Five Months Vs Chemotherapy as First-line Treatment for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02 Business Wire 2:30 AM

-- October 18, 2025 --

ENHERTU (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial Business Wire 10:35 AM

ENHERTU Reduced the Risk of Disease Recurrence or Death by 53% Versus T-DM1 in Patients with High-Risk HER2 Positive Early Breast Cancer Following Neoadjuvant Therapy in DESTINY-Breast05 Phase 3 Trial Business Wire 10:30 AM

ENHERTU Followed by THP Before Surgery Resulted in a Pathologic Complete Response in 67% of Patients with High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial Business Wire 10:30 AM

ENHERTU (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial Business Wire 10:30 AM

-- October 17, 2025 --

TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps Business Wire 4:17 PM

DATROWAY Plus Rilvegostomig Showed Promising Tumor Responses in Patients with Metastatic Urothelial Cancer in TROPION-PanTumor03 Phase 2 Trial Business Wire 10:00 AM

IMFINZI (durvalumab) regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial Business Wire 8:10 AM

IMFINZI (durvalumab)-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial Business Wire 8:00 AM

-- October 15, 2025 --

AstraZeneca unveils expanded manufacturing facility in Texas Business Wire 10:00 AM

-- October 13, 2025 --

AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO Business Wire 7:00 AM

-- October 9, 2025 --

AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs Business Wire 12:30 PM

Turbine Launches Collaboration with AstraZeneca, Leveraging Turbine's Virtual Disease Models to Rationalize ADC Discovery PRNewswire 6:00 AM

-- October 7, 2025 --

Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension Business Wire 7:00 AM

-- October 6, 2025 --

DATROWAY (datopotamab deruxtecan-dlnk) improved OS and PFS in TROPION-Breast02 Business Wire 7:00 AM

DATROWAY Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival as First-Line Therapy for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02 Business Wire 2:30 AM

-- October 1, 2025 --

ENHERTU Followed by THP Supplemental Biologics License Application Accepted in the U.S. for Patients with High-Risk HER2 Positive Early-Stage Breast Cancer Prior to Surgery Business Wire 7:00 AM

-- September 29, 2025 --

ENHERTU (fam-trastuzumab deruxtecan-nxki) demonstrated highly statistically significant and clinically meaningful improvement in invasive disease-free survival vs. T-DM1 in DESTINY-Breast05 Phase III trial Business Wire 7:00 AM

ENHERTU Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Invasive Disease-Free Survival Versus T-DM1 in DESTINY-Breast05 Phase 3 Trial in Patients with High-Risk Early Breast Cancer Following Neoadjuvant Therapy Business Wire 2:30 AM

-- September 26, 2025 --

AstraZeneca launches direct-to-consumer platform to expand access to medications for US patients, including those living with chronic conditions Business Wire 9:00 AM

-- September 24, 2025 --

ENHERTU (fam-trastuzumab deruxtecan-nxki) plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer Business Wire 7:00 AM

ENHERTU Plus Pertuzumab Granted Priority Review in the U.S. as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer Business Wire 2:30 AM

-- September 22, 2025 --

SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer PRNewswire 8:00 AM

-- September 18, 2025 --

AIRSUPRA (albuterol/budesonide) US prescribing information updated to reflect the statistically significant severe exacerbation risk reduction in patients with mild asthma compared with albuterol Business Wire 7:00 AM

-- September 17, 2025 --

SAPHNELO self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis Business Wire 7:05 AM